Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Common Equity (2024 - 2026)

Carlsmed filings provide 2 years of Common Equity readings, the most recent being $98.9 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 239.98% to $98.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $98.9 million, a 239.98% increase, with the full-year FY2025 number at $98.9 million, up 239.98% from a year prior.
  • Common Equity hit $98.9 million in Q4 2025 for Carlsmed, down from $106.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $106.7 million in Q3 2025 to a low of -$83.1 million in Q2 2025.